Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if offering long-acting injectable cabotegravir (CAB-LA) as an additional HIV prevention choice among oral PrEP-experienced men who have sex with men (MSM) in France can significantly increase the sustained PrEP use over time and the PrEP coverage of at-risk sexual risk behaviors.
Phase:
PHASE3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Treatments:
cabotegravir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir